Further prospective multicenter studies evaluating a broader array of autoantibodies and responses to anti-fibrotic therapy are needed to fully explore the prognostic significance of ANA in individuals with IPF. This evidence concerns the gene BTG3 and idiopathic pulmonary fibrosis.